Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor.

Florian Full¹, Manfred Lehner, Veronika Thonn

¹Virologisches Institut, Universitätsklinikum Erlangen, Schlossgarten 4, Erlangen, Germany.

Journal of Virology

|February 12, 2010

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Functional dissection of HCMV gB's autonomous fusion activity provides insights into how polymorphisms in clinical isolates confer distinct characteristics.

mBio·2026

Same author

Augmenting CAR T cell functionality and metabolism through CD39 downtuning.

Molecular therapy. Oncology·2026

Same author

Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Molecular therapy. Oncology·2026

Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026

Same author

Low frequency variants can predetermine antiviral drug resistance development in herpes simplex virus type 1.

PLoS pathogens·2026

Same author

DHODH Inhibitors Based on the Vidofludimus Scaffold Containing Carboxylic Acid Bioisosteres Exert a Superior Broad-Spectrum Antiviral Activity.

Journal of medicinal chemistry·2026

New chimeric immunoreceptor (cIR)-engineered T cells target Cytomegalovirus (CMV) glycoprotein B. This approach offers a novel, HLA-independent immunotherapy for high-risk hematopoietic stem cell transplant patients with CMV infection.

Area of Science:

Immunology
Transplantation Medicine
Virology

Background:

Cytomegalovirus (CMV) infection poses significant risks, including morbidity and mortality, for patients undergoing hematopoietic stem cell transplants (HSCT).
Current adoptive T cell immunotherapy faces limitations, particularly in high-risk scenarios involving CMV-positive HSCT recipients and CMV-negative stem cell donors.

Purpose of the Study:

To develop a novel, HLA-independent immunotherapy for CMV infection in high-risk HSCT patients.
To engineer primary human T cells to target CMV glycoprotein B using a chimeric immunoreceptor (cIR).

Main Methods:

Human effector T cells were engineered to express a cIR specific for CMV glycoprotein B.
The antiviral effector functions of these cIR-engineered T cells were evaluated.

More Related Videos

Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs

Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs

Published on: September 10, 2017

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 16, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs

Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs

Published on: September 10, 2017

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Main Results:

The cIR-engineered T cells demonstrated potent antiviral effector functions, including cytokine production and cytolysis.
This represents the first description of cIR-redirected CMV-specific T cells.

Conclusions:

Engineered T cells targeting CMV glycoprotein B provide a promising new strategy for immunotherapy.
This approach offers a potential solution for HLA-independent treatment of CMV infection in high-risk HSCT patients.